RxDoctor Payments Data

Dennis Cortes, MD

Internal Medicine · Miramar, FLNPI 1013198118

Payments from drug & device makers

$12,198in general payments, 2019–2025

Across 658 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$612
  • Kowa Pharmaceuticals America, Inc.$611
  • plus $6K from 51 others

What the payments were for

  • Consulting fees$190%
  • Food & beverage$12,08599%
  • Education$350%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk107$1,859
AbbVie(2 entities)71$1,238
Pfizer61$1,137
AstraZeneca56$1,054
Lilly USA, LLC38$612
Kowa Pharmaceuticals America, Inc.34$611
Bayer23$566
Sanofi-aventis U.S. LLC23$466
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$281
Abbott14$262
GSK12$256
Kvk-tech, Inc.29$224
Biohaven Pharmaceutical Holding Company Ltd.9$192
Insulet Corporation9$186
Otsuka America Pharmaceutical, Inc.8$182
Biohaven Pharmaceuticals, Inc.11$178
Verity Pharmaceuticals Inc.8$175
Dexcom, Inc.7$173
Amarin Pharma, Inc.10$172
Astellas Pharma US Inc8$161
Supernus Pharmaceuticals, Inc.10$152
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$144
Shield Therapeutics Inc3$128
Acella Pharmaceuticals, LLC6$105
Phathom Pharmaceuticals, Inc.5$99
Teva Pharmaceuticals USA, Inc.6$93
Takeda Pharmaceuticals U.S.A., Inc.4$89
Daiichi Sankyo Inc.4$86
Exact Sciences4$86
Clarus Therapeutics Inc.4$82
Mannkind Corporation2$78
Novartis4$76
Idorsia Pharmaceuticals US Inc3$73
Antares Pharma, Inc.3$72
IBSA Pharma Inc.4$72
Medicure Pharma Inc.2$71
Zyla Life Sciences, Inc.3$66
Amgen3$56
Shire North American Group Inc3$53
Hikma Pharmaceuticals USA3$49
Axsome Therapeutics, Inc.2$49
Jazz Pharmaceuticals Inc.2$47
Genentech USA, Inc.2$42
Scilex Pharmaceuticals Inc.2$37
Aytu Biopharma, Inc.2$35
Phadia US Inc.2$33
Ironwood Pharmaceuticals, Inc2$30
Sunovion Pharmaceuticals Inc.1$26
Boehringer Ingelheim1$26
Eisai Inc.1$25
Intra-sana Laboratories1$24
Sumitomo Pharma America, Inc.1$23
Nabriva Therapeutics, PLC1$20
Vertex1$20
E.r. Squibb & Sons, L.L.C.1$18
Smith+Nephew1$17
Arbor Pharmaceuticals, Inc.1$15

How this compares

$12,198 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$87,358
Medicare patients
163
Services billed
1,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban171$159,858
OzempicSemaglutide35$56,904
MounjaroTirzepatide45$56,512
Soliqua 100-33Insulin Glargine/Lixisenatide53$51,307
XareltoRivaroxaban34$36,166
FarxigaDapagliflozin Propanediol30$29,195
JanuviaSitagliptin Phosphate18$24,824
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$21,758
ProliaDenosumab12$20,093
MyrbetriqMirabegron16$18,319
RybelsusSemaglutide13$16,245
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$13,454
LinzessLinaclotide19$13,281
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$12,299
LantusInsulin Glargine,hum.Rec.Anlog32$10,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$1,137$167,685192 claims
Novo NordiskOzempic, Rybelsus$1,859$73,14948 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$466$61,75285 claims
Lilly USA, LLCMounjaro$612$56,51245 claims
AstraZenecaFarxiga, Symbicort$1,054$37,80653 claims
GSKTrelegy Ellipta, Breo Ellipta$256$29,26040 claims
AmgenProlia$56$20,09312 claims
Astellas Pharma US IncMyrbetriq$161$18,31916 claims
AbbVieLinzess, Synthroid$1,238$17,43573 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miramar

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →